Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792415 | 0.79 | TSHR (0.41) | TSHRLPAR3 | |
| SCHEMBL6798591 | 0.79 | TSHR (0.41) | TSHRLPAR3 | |
| SCHEMBL6796097 | 0.79 | TSHR (0.41) | TSHRLPAR3 | |
| SCHEMBL6797613 | 0.79 | TSHR (0.41) | TSHRLPAR3 | |
| SCHEMBL6797179 | 0.79 | TSHR (0.41) | TSHRLPAR3 | |
| SCHEMBL6804297 | 0.79 | ACLY (0.39) | MAPTLMNAACLYUSP2CYP3A4 | |
| SCHEMBL6804293 | 0.79 | ACLY (0.39) | MAPTLMNAACLYUSP2CYP3A4 | |
| SCHEMBL3119005 | 0.78 | TSHR (0.44) | TSHRALDH1A1MAPTABCC4LMNA | |
| SCHEMBL2521791 | 0.76 | TSHR (0.48) | TSHRALDH1A1MAPTABCC4LMNA | |
| SCHEMBL21286888 | 0.76 | TSHR (0.43) | TSHRALDH1A1MAPTABCC4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067870-A1 | Fragrance raw materials aldehydes and pro-fragrances having a tertiary alpha carbon atom | THE PROCTER & GAMBLE COMPANY | 2004-04-08 | — | — | US | disclosed |
| EP-1171556-A1 | FRAGRANCE RAW MATERIALS ALDEHYDES AND PRO-FRAGRANCES HAVING A TERTIARY ALPHA CARBON ATOM | THE PROCTER & GAMBLE COMPANY (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000063329-A1 | FRAGRANCE RAW MATERIALS ALDEHYDES AND PRO-FRAGRANCES HAVING A TERTIARY ALPHA CARBON ATOM | THE PROCTER & GAMBLE COMPANY (US) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067870-A1 | Fragrance raw materials aldehydes and pro-fragrances having a tertiary alpha carbon atom | CUTA, TRPA1, HRH1 | TSHR 4138/4885ALDH1A1 51/4885MAPT 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.